Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
6.37
-0.34 (-5.07%)
At close: Jul 14, 2026, 4:00 PM EDT
6.44
+0.07 (1.10%)
After-hours: Jul 14, 2026, 6:27 PM EDT
ARCT Revenue
Arcturus Therapeutics Holdings had revenue of $2.06M in the quarter ending March 31, 2026, a decrease of -92.99%. This brings the company's revenue in the last twelve months to $54.71M, down -61.92% year-over-year. In the year 2025, Arcturus Therapeutics Holdings had annual revenue of $82.03M, down -46.14%.
Revenue (ttm)
$54.71M
Revenue Growth
-61.92%
P/S Ratio
3.36
Revenue / Employee
$492,883
Employees
111
Market Cap
181.05M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 82.03M | -70.28M | -46.14% |
| Dec 31, 2024 | 152.31M | -14.49M | -8.69% |
| Dec 31, 2023 | 166.80M | -39.20M | -19.03% |
| Dec 31, 2022 | 206.00M | 193.64M | 1,566.79% |
| Dec 31, 2021 | 12.36M | 2.82M | 29.56% |
| Dec 31, 2020 | 9.54M | -11.25M | -54.12% |
| Dec 31, 2019 | 20.79M | 5.04M | 31.97% |
| Dec 31, 2018 | 15.75M | 2.76M | 21.20% |
| Dec 31, 2017 | 13.00M | -7.38M | -36.23% |
| Dec 31, 2016 | 20.38M | 14.24M | 232.06% |
| Dec 31, 2015 | 6.14M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 76.38M |
| MediWound | 14.48M |
| Equillium | 4.39M |
| Cibus | 4.29M |
| Korro Bio | 3.84M |
| NRx Pharmaceuticals | 2.29M |
| Humacyte | 2.02M |
ARCT News
- 12 days ago - Arcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth - TheFly
- 12 days ago - Arcturus announces collaboration with Thermo Fisher to advance ARCT-032 - TheFly
- 12 days ago - Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis - Business Wire
- 12 days ago - Arcturus Therapeutics initiated with a Buy at Freedom Broker - TheFly
- 14 days ago - Arcturus could halve the grid's electrical losses using its nano-infused copper - TechCrunch
- 5 weeks ago - Arcturus Therapeutics Holdings Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference - Business Wire
- 2 months ago - Arcturus Therapeutics Holdings Transcript: 16th Annual LD Micro Invitational Conference - Transcripts